Figure 2. Tumor regression is coupled with autoimmune diabetes, and both clinical events are CD8⁺ T cell dependent.

(A and F) gp33-specific CD8⁺ T cell responses were evaluated in B16-gp33 tumor–bearing RIP-gp mice at the designated time point after administration of the indicated treatment (0 dpi) and are expressed as the percentage of peripheral circulation CD8⁺ T cells that produced IFN-γ upon stimulation with the gp33 peptide. (B and G) Tumor volume (mm³) was assessed at the indicated time points. (C and I) Survival of and (D and H) percentage of diabetes in the treated mice. Results of the combination therapy (A–D) and the effect of T cell subset depletion (F–I). Shown in E are representative pancreatic sections from treated mice probed immunohistochemically with an anti-insulin mAb. Scale bars: 20 μm. Data for A–C represent 1 of 3 experiments; n = 4 per group (VSV-gp33) and n = 5 per group (PBS, P14T_CM cells, VSV-GFP, P14T_CM cells plus VSV-GFP. Data for F–I are representative of 2 independent experiments; n = 5 per group (anti-CD8 [α-CD8] and anti-CD4 [α-CD4]) and n = 4 per group (anti-isotype [α-Isotype]). *P < 0.05 and **P < 0.01, by 1-way ANOVA with Holm-Sidak correction for multiple comparisons (A and F) and log-rank (Mantel-Cox) test (C, D, H, and I).